Medical Bulletin Board

Aspen Malnutrition Awareness Week: Helping Gi Clinicians Intervene And Treat Malnutrition

Read Article

On October 4-8, 2021, the American Society for Parenteral and Enteral Nutrition (ASPEN) will launch its annual campaign to educate healthcare professionals on detecting, intervening, and treating malnutrition. The 2021 program includes live CME webinars, special interactive Zoom discussions, and a wide array of complimentary videos, podcasts, tools, and resources addressing malnutrition.

The offerings will be of keen interest to gastroenterologists, as malnourished patients have longer hospital stays, higher readmission rates, and increased hospital costs and inpatient death rates.

The American Society for Gastrointestinal Endoscopy and the Society of Gastroenterology Nurses and Associates are among the growing number of more than 110 organizations that support Malnutrition Awareness WeekTM.

Five of the live webinars, which are free to ASPEN members and supporting organizations, provide continuing medical education credits. They will be offered on the following dates:

October 4: Malnutrition Diagnosis and Documentation: Strategies for Success

October 5: Addressing Malnutrition in COVID-19 Patients: From Hospital to Home

October 6:Collaborating with NonNutrition Clinicians on Malnutrition Strategies

October 7: Ramifications of Nutrient Shortages in the Neonatal Population

October 8: Applying Latest Findings from Notable Malnutrition Publications to Your Practice

Webinar capacity is limited so early registration is strongly recommended.

All other Malnutrition Awareness Week educational materials are available free of charge, including short, on-demand videos that will cover a range of topics including performing nutrition assessment via telehealth in inpatient and outpatient settings.

The videos, podcasts, resources, and other tools, ranging from clinician guides to patient handouts, will be released throughout September and October.

To register for the webinars and to access the complimentary resources, visit: nutritioncare.org/PG-MAW

About ASPEN

The American Society for Parenteral and Enteral Nutrition (ASPEN) is dedicated to improving patient care by advancing the science and practice of nutrition support therapy and

metabolism. It is an interdisciplinary organization whose members are involved in the provision of clinical nutrition therapies, including parenteral and enteral nutrition. With members from around the world, ASPEN is a community of dietitians, nurses, nurse practitioners, pharmacists, physicians, scientists, students, and other health professionals from every facet of nutrition support clinical practice, research, and education.

For more information about ASPEN, please visit:

nutritioncare.org

Download Tables, Images & References

Medical Bulletin Board

Fujifilm Unveils Advanced Image Enhancement Technology Upgrade For Eluxeo Endoscopic Imaging System At Sages 2021

Read Article

This technology is the first in-market solution to enable visualization of hemoglobin oxygen saturation (StO2) levels in tissue during laparoscopic and endoluminal procedures

Lexington, Mass. – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of endoscopic and endosurgical imaging technology, announces the commercial launch of the ELUXEO® 7000X System, a new video imaging technology developed to enable real-time visualization of hemoglobin oxygen saturation (StO2) levels in tissue using laparoscopic and/or endoluminal imaging.

The ELUXEO 7000X is an upgrade to the company’s ELUXEO® Endoscopic Imaging System, and was unveiled at the annual Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) conference, held August 31 – September 3 at Sands Expo Convention Center in Las Vegas Nevada. The ELUXEO Endoscopic Imaging System revolutionized endoscopic visualization when it was introduced to the U.S. market in 2018 with its proprietary 4-LED Multi-light technology. The ELUXEO 7000X System employs 5-LED technology to enable this enhanced imaging capability.

Enabling the visualization and analysis of StO2 levels helps surgeons more accurately identify potentially ischemic tissue, better positioning surgeons to address and prevent tissue necrosis.

Today’s standard for visualizing tissue perfusion is to leverage fluorescent imaging using indocyanine green (ICG) dye – a method in which an injectable dye circulates through the bloodstream and is excited using nearinfrared light. Physicians then use that excited dye to identify blood flow. Fujifilm’s innovation was developed to address potential limitations resulting from ICG:

  • Intravenous dye injections are not required prior to imaging.
  • GI tract observation time frame can be extended as liver filtration of ICG dye is no longer a factor.

In addition, ICG does not allow physicians to detect potential ischemic tissue during endoluminal procedures, making the ELUXEO 7000X the only product on the market to enable this visualization via StO2 measurements.

The technology was granted “breakthrough device” designation by the U.S. Food and Drug Administration (FDA) in September, 2020, and received 510(k) clearance from the FDA on June 30, 2021.

The endosurgical research team at Fujifilm has been working closely on clinical usage of the technology with key opinion leaders from top medical centers in the United States and Japan.

“I find the ELUXEO 7000X System to be a game changing technology in the fields of MIS and endosurgery,” says Paul Curcillo, MD, FACS, Department of Surgical Oncology, Division of Minimally Invasive Surgery, Fox Chase Cancer Center. “The ability for real-time assessment of StO2 allows me to identify tissue necrosis

  • Intravenous dye injections are not required prior to imaging.
  • GI tract observation time frame can be extended as liver filtration of ICG dye is no longer a factor.

In addition, ICG does not allow physicians to detect potential ischemic tissue during endoluminal procedures, making the ELUXEO 7000X the only product on the market to enable this visualization via StO2 measurements.

The technology was granted “breakthrough device” designation by the U.S. Food and Drug Administration (FDA) in September, 2020, and received 510(k) clearance from the FDA on June 30, 2021.

The endosurgical research team at Fujifilm has been working closely on clinical usage of the technology with key opinion leaders from top medical centers in the United States and Japan.

“I find the ELUXEO 7000X System to be a game changing technology in the fields of MIS and endosurgery,” says Paul Curcillo, MD, FACS, Department of Surgical Oncology, Division of Minimally Invasive Surgery, Fox Chase Cancer Center. “The ability for real-time assessment of StO2 allows me to identify tissue necrosis

without factoring in time restrictions and the need for consumables. In addition, we can use it in any laparoscopic case we are doing with our existing ELUXEO endoscopic imaging system.”

“Our ELUXEO product portfolio is engineered to revolutionize conventional minimally-invasive and endoluminal procedures and to raise the standard of patient care,” said Taisuke Fujita, vice president, Endoscopy Division, FUJIFILM Medical Systems U.S.A. “Fujifilm continues to draw on our traditional medical imaging and optical expertise to meet today’s needs of surgeons across the entire clinical spectrum.”

Same suite, single cart

The Fujifilm ELUXEO System allows minimally invasive and endoluminal procedures to be performed in the same suite using a single tower, reducing the amount of valuable space needed in the OR. 

“The American Board of Surgery now requires surgeons to be trained in flexible endoscopy, powering the rise in surgeons’ use of less invasive endoluminal techniques,” added Fujita. “The ELUXEO Endoscopic Imaging System is a surgical device disruptor, empowering enhanced procedural workflow, and optimizing space in surgical suites.” The ELUXEO Endoscopic Imaging System is uniquely engineered with 4-LED Multi-light technology, combining brilliantly clear white light imaging with Linked Color Imaging

(LCI®) and Blue Light Imaging (BLI) modes. The result is unparalleled image clarity and visualization in full high definition to enhance observation, improve detection, and enable full characterization. Surgeons using LCI can clearly see and distinguish anatomical structures of tissue, fat, and vessels to more accurately and precisely determine incision placement.

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of unrivaled diagnostic imaging products and medical informatics solutions that meet the evolving needs of healthcare facilities today and into the future.

Medical imaging solutions span digital radiography (DR), detectors, portables and suites, mammography systems with digital breast tomosynthesis, computed tomography solutions for oncology and radiology applications, as well as technologically advanced flexible and surgical endoscopy solutions. Fujifilm enables interoperability through its Systems Integration offering as well as its comprehensive, AI-supported Synapse® Enterprise Imaging portfolio, which includes the TeraMedica Division of Fujifilm. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit healthcaresolutionsus.fujifilm.com.   FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to

the various fields including healthcare, highly functional materials, document solutions and imaging products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2021, the company had global revenues of $21 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship.

For more information, please visit: fujifilmholdings.com

Download Tables, Images & References

Medical Bulletin Board

Phathom Pharmaceuticals Submits Two Ndas to U.S. Fda for Vonoprazan-based Treatment Regimens for the Treatment of H. Pylori Infection

Read Article

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced that it has submitted two new drug applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and vonoprazan in combination with amoxicillin (vonoprazan dual therapy) as a treatment for Helicobacter pylori (H. pylori) infection in adults. With current standard of care therapies, H. pylori eradication rates have declined in the U.S. If approved, vonoprazan-based treatments offer two new therapeutic options that have demonstrated superior eradication rates as compared to standard of care lansoprazole-based triple therapy.  “The submission of these NDAs is the first step towards addressing the declining H. pylori eradication rates in the U.S. and providing new potential treatment options for the millions of H. pylori sufferers in need of more efficacious treatments,” said Azmi Nabulsi, M.D., Chief Operating Officer at Phathom. “Today’s announcement underscores Phathom’s commitment to changing the treatment landscape for acid-related diseases. If approved, patients and healthcare providers would have two novel options to combat this highly prevalent bacterial infection. We look forward to working with the FDA to advance these vonoprazan-based treatment regimens toward approval. If approved, we anticipate launch in the U.S. in the second half of 2022.”

These NDAs are based on the positive data previously announced from Phathom’s pivotal Phase 3 PHALCON-HP trial, the largest U.S. registrational trial ever conducted for H. pylori. The study evaluated eradication rates of H. pylori infection using vonoprazan triple therapy and vonoprazan dual therapy compared to lansoprazolebased triple therapy. Vonoprazan triple therapy and vonoprazan dual therapy successfully met the study’s primary non-inferiority endpoints and all secondary endpoints, demonstrating superior eradication rates versus lansoprazole-based triple therapy among all patients including in patients with clarithromycin resistant strains of H. pylori.

The FDA has previously designated vonoprazan triple therapy and vonoprazan dual therapy as qualified infectious disease products (QIDP) and awarded them Fast Track designation, in each case, for the treatment of H. pylori infection. In connection with the NDA submissions, Phathom requested Priority Review, which, if granted, will shorten the review period from 10 months to 6 months following FDA acceptance of the submissions for filing.

About Helicobacter pylori (H. pylori) infection

H. pylori is a bacterial pathogen that is estimated to infect over 200 million individuals in the United States and Europe. Approximately 50% of the world and 36% of the US population are infected with the bacterium.1 In many cases, H. pylori is acquired in childhood and through intrafamilial transmission.2 As a result of the chronic inflammation induced by H. pylori infection, infected patients develop a range of pathologies including dyspepsia, peptic ulcer disease, gastric cancer, and mucosaassociated lymphoid tissue (MALT) lymphoma.3 Studies have found that roughly 1 in 5 patients treated for H. pylori will fail first line therapy when using standard clarithromycin triple therapy.2,4

About PHALCON-HP

PHALCON-HP was a randomized, multicenter,

Phase 3 trial that enrolled 1046 patients of which 992 patients with a confirmed H. pylori infection were randomized to one of three arms: vonoprazan 20 mg administered twice a day (BID) and amoxicillin 1g administered three times a day (TID) (n=324); vonoprazan 20 mg BID, amoxicillin 1g BID and clarithromycin 500 mg BID (n=338); and lansoprazole 30 mg BID, amoxicillin 1g BID and clarithromycin 500 mg BID (n=330). Each treatment regimen was administered for 14 days. Diagnoses of infection and test of cure were confirmed by 13C-urea breath test. Additional efficacy analyses were

conducted using the prespecified per protocol population (n=822), a subset of the mITT population comprised of patients who were protocol compliant.

About Vonoprazan

Vonoprazan is an investigational, oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown the potential to have rapid, potent, and durable anti-secretory effects as a single agent in the treatment of gastroesophageal reflux disease (GERD) and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. The FDA has awarded qualified infection disease product (QIDP) status and granted Fast Track designation to vonoprazan in combination with both amoxicillin and clarithromycin and with amoxicillin alone for the treatment of H. pylori infection. Phathom in-licensed the U.S., European, and Canadian rights to vonoprazan from Takeda, which completed 19 Phase 3 trials for vonoprazan and received marketing approval in Japan and numerous other countries in Asia and Latin America.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United

States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acidrelated disorders.

For more information about Phathom, visit the Company’s website at:

phathompharma.com or follow the Company on social media: LinkedIn at:

linkedin.com/company/phathompharma and Twitter @PhathomPharma

Forward Looking Statements

Phathom cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forwardlooking statements include, but are not limited to, statements regarding: the potential acceptance and approval by the FDA of our NDAs for vonoprazan; the ability of vonoprazan-based treatments to address declining H. pylori eradication rates; and our plans to commercially launch vonoprazan in the second half of 2022. The inclusion of forwardlooking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom’s business, including, without limitation: the FDA may disagree that the existing safety and efficacy data is sufficient to accept or approve the NDAs; the inherent risks of clinical development of vonoprazan; Phathom’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/ or commercialization, or may result in recalls or product liability claims; Phathom’s ability to obtain and maintain intellectual property protection for vonoprazan; Phathom’s ability to comply with its license agreement with Takeda; Phathom’s ability to maintain undisrupted business operations due to the COVID-19 coronavirus, including delaying or otherwise disrupting its clinical trials, manufacturing and supply chain; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

  1. Hooi et al. Gastroenterology. 2017;153:420.
  2. Chey et al. Am J Gastroenterol.2017;112:212.
  3. Malfertheiner et al. Gut. 2017;66:6.
  4. Alsamman et al. Dig Dis Sci. 2019;64:2893.

Download Tables, Images & References

NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #214

Ileostomy and C. difficile Infection

Read Article

Clostridioides difficile is a common cause of infectious colitis, and a less recognized cause of enteritis. There have been several reported cases of C. difficile enteritis in patients who have an end ileostomy after a total colectomy. Like colitis caused by C. difficile, C. difficile enteritis can have a wide range of clinical manifestations, ranging from diarrhea to septic shock, although the most common presenting symptom is increased ileostomy output. Risk factors include recent antibiotic use, proton pump inhibitor use, inflammatory bowel disease, and immunosuppression. Diagnosis and treatment are the same as for C. difficile colitis, as diagnosis is confirmed with stool toxin assays and first line treatment is oral vancomycin. C. difficile enteritis is a rare disease that can have a fatal outcome, and thus providers must have a high index of suspicion to reduce morbidity and mortality.

INTRODUCTION

Clostridioides difficile (CD) is a Gram-positive, end-organ failure and death. Less appreciated is its spore-forming, toxin-producing bacillus, that role as a cause of small bowel enteritis in patients is the most common etiology of nosocomial who have undergone a total colectomy with an infectious diarrhea, and antibiotic-associated end ileostomy or ileal pouch-anal anastomosis.
diarrhea.1 The incidence of C. difficile has been increasing rapidly since the early 2000s, in part due to the highly virulent NAP1/BI/027 strain.2 Lower clinical cure rates, increased recurrence rates, more severe disease, and higher 14-day mortality rates have been seen in patients infected with this strain.3

C. difficile infection (CDI) is well known to affect the colon, resulting in a large range of clinical outcomes, ranging from relatively asymptomatic diarrhea, to toxic megacolon and fulminant colitis which can result in hemodynamic instability,

As CDI enteritis is rare, much of our knowledge of the disease comes from case reports, with approximately 60 cases reported in the literature to date.2,4-22

CDI enteritis is associated with increased hospital length of stay (LOS) and health care costs, poor patient quality of life, and high mortality rate approaching 30%.2,4 This high mortality rate is likely due to delay in diagnosis given the rarity of the illness. Unfortunately, many patients are diagnosed only at the time of autopsy where pseudomembranes are identified within the small intestine.10 Luckily, with increased recognition of the disease and early diagnosis, prognosis is improving. Here, we aim to summarize the current evidence regarding CDI enteritis, specifically in the

subset of patients who have had a total colectomy and an end ileostomy, and increase awareness of this underdiagnosed, yet potentially fatal disease. Risk Factors and Pathogenesis

Risk factors for CDI enteritis include recent antibiotic and proton pump inhibitor (PPI) use, ICU or prolonged hospital stay, increasing age, immunosuppression, history of gastrointestinal surgery of the colon, and inflammatory bowel disease (IBD).4,14 Approximately 70% of patients have been found to have antibiotic usage in the 4 weeks prior to presentation, and approximately 35% have been found to have a medical condition that might lead to an immunocompromised state.2,9 Similar to colonic CDI, patients with a history of IBD are also at an increased risk of developing CDI enteritis. Approximately 40-50% of patients with CDI enteritis have a history of IBD.2,9 The abnormal gut mucosal immune response in IBD patients may play a role in increasing susceptibility to gastrointestinal infection amongst these patients.14

The pathogenesis of CDI enteritis in patients with an end ileostomy is unclear; however, several hypotheses have been suggested. There appears to be an increase in susceptibility to disease as a result of the histologic and microbiologic similarity between the small bowel and colon that may develop after a total colectomy. A competent ileocecal valve has been suggested to inhibit small bowel colonization with colonic bacterial flora. With removal of the colon and ileocecal valve, the small bowel flora changes such that the neoterminal ileum is characterized by colonic-type fecal flora, thereby making it more susceptible to overgrowth with CD.4,14 Patients with a history of CDI colitis are more susceptible to developing CDI enteritis, especially in the early postoperative phase, as a result of bacterial migration from the colon to the small bowel.14 Patients also develop colonic-type metaplasia and partial villous atrophy of the terminal end of the ileostomy as a result of alterations in fecal flow, thereby increasing its similarity to the colonic environment.2,4,8

Symptoms and Diagnosis

Patients with CDI enteritis may present with nonspecific symptoms. The most common presenting symptom amongst case reports is increased ileostomy output, which may lead to dehydration or acute kidney injury.14 Diagnosis is often missed in those with an ileostomy, as watery diarrhea is expected, especially in the immediate postoperative period. Additionally, increased ileostomy output could have several other causes, including infection and partial obstruction, etc. Other symptoms include ileus, fever, abdominal or pelvic pain, and abdominal cramping. Depending on the severity of disease and degree of dehydration, some patients may present with hemodynamic instability, including tachycardia and hypotension.4,6,10 However, many patients are non-toxic with normal vital signs, and may or may not be febrile.5,8 Physical exam findings can include diffuse tenderness without signs of peritonitis.2,4,6 Laboratory and imaging studies may aid in the diagnosis of CDI enteritis. Patients will often have leukocytosis. In severe cases, patients may have evidence of acute kidney injury and electrolyte derangements as a result of dehydration.12,18 A computed tomography (CT) scan can show findings of distended, fluid-filled small bowel in the presence of mesenteric fat stranding and free intraabdominal fluid suggestive of enteritis.19 Although this is also nonspecific, the combination of laboratory derangements, CT scan findings and patient’s symptoms should raise one’s clinical index of suspicion and aid in the diagnosis of CDI enteritis.

CDI enteritis should be considered in any patient with an ileostomy presenting with the aforementioned symptoms, especially if they have a history of recent antibiotic use, IBD, or immunosuppression. Diagnosis is confirmed by the presence of CD toxin in a stool sample by polymerase chain reaction (PCR) or enzyme immunoassay.1

Management

Management of CDI enteritis parallels that of CDI colitis, and is dictated by disease severity. The first line treatment for mild/moderate disease is a 10day course of oral vancomycin or fidaxomicin. Metronidazole is a second-line agent but should be avoided in patients with associated IBD due to poor absorption. Recurrence may be treated with For a second recurrence, one should consider fidaxomicin, pulse tapered regimen of vancomycin, or rifaximin regimen following PO vancomycin.4 Additional recurrences may necessitate consideration of a fecal microbiota transplant administered via upper endoscopy or ileoscopy through the stoma itself.4,24 As with CDI colitis, severe cases should be treated with antibiotics, supportive care and early consideration for surgical intervention.4

C. Difficile in Patients with

Ileal Pouch-Anal Anastomosis

Total colectomy with ileal pouch-anal anastomosis (IPAA), commonly referred to as a “J-pouch,” is the operation of choice for many patients with treatment-refractory ulcerative colitis, as it may cure the patient’s disease without necessitating a permanent ileostomy. Pouchitis, or inflammation of the ileal pouch, is the most common complication after IPAA, with cumulative incidence approaching 45% at 5 years.23 It can be caused by infection, recurrence of IBD, and irritation to the pouch mucosa. CDI of the ileal pouch has been recognized as a possible cause of pouchitis. Approximately 10% of symptomatic patients seen at a tertiary referral center for pouch dysfunction are diagnosed with CDI of the pouch.24

Unlike CDI enteritis, postoperative antibiotic exposure and use of immunosuppressive agents or PPIs do not appear to be associated with CDI pouchitis.24 Rather, risk factors include male gender, recent hospitalization, and pre-surgery antibiotic usage.24-26 Patients with an ileal pouch are susceptible to CDI due to similarities of the pouch with the colon at both physiological and structural levels.24 Fecal stasis within the pouch promotes gut microbial dysbiosis and colonic metaplasia of the ileal mucosa, which may predispose to CDI infection and colonization.23

Patients commonly present with abdominal

or pelvic pain and increased stool frequency.23,27,28 Diagnosis is confirmed with stool toxin assays, and endoscopic visualization by pouchoscopy may be of value.24 CDI should be considered in ileal pouch patients particularly if there is a change to their usual symptomology and if the episode of pouchitis appears to be refractory to antibiotic management.24

Testing for CDI should be considered in pouch patients presenting with fever, urgency, increased stool frequency, hematochezia, incontinence, and abdominal or pelvic pain.23

Treatment for CDI pouchitis is the same as treatment for CDI colitis and enteritis, with oral vancomycin being the first line agent. Although exploratory, fecal microbiota transplantation may be useful in severe or antibiotic-refractory cases.24 Overall, the prognosis is relatively good, and most patients are successfully treated with antibiotics; however more severe cases of CDI pouchitis have also been reported. There is one case reported in the literature that required pouch excision with conversion to ileostomy,29 and one case of fulminant CDI resulting pseudomonas aeruginosa septicemia, intravascular coagulopathy, acute renal failure, hemorrhagic ascites, respiratory failure, and eventual death.30

SUMMARY AND RECOMMENDATIONS

Although better known for causing colitis,

Clostridioides difficile is a rare cause of enteritis, particularly in patients who have undergone a total colectomy. Physicians treating patients with end ileostomies and ileal pouch-anal anastomoses should have a high index of suspicion for C. difficile infection in any patient presenting with increased stool output, abdominal cramping, and/or fever, especially if they have a history of recent antibiotic use, PPI use, inflammatory bowel disease, or an immunosuppressed state. CDI enteritis can be a highly morbid and even fatal disease, and thus prompt recognition and initiation of treatment is imperative to improve outcomes. See Table 1 for a summary of identification and management of CDI enteritis.

References

  1. Dupont HL. Diagnosis and management of Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11(10):1216-23.
  2. Dineen SP, Bailey SH, Pham TH, et al. Clostridium difficile enteritis: A report of two cases and systematic literature review. World J Gastrointest Surg. 2013;5(3):37-42.
  3. Marsh JW, Arora R, Schlackman JL, et al. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol. 2012;50(12):4078-82.
  4. Aujla AK, Averbukh LD, Potashinsky A, et al. A Rare Case of Clostridium difficile Enteritis: A Common Bug in an Uncommon Place. Cureus. 2019;11(4):e4519.
  5. Causey MW, Spencer MP, Steele SR. Clostridium difficile enteritis after colectomy. Am Surg. 2009;75(12):1203-6.
  6. Freiler, JF, Durning SJ, Ender PT. Clostridium difficile small bowel enteritis occurring after total colectomy. Clin Infect Dis. 2001;33(8):1429-32.
  7. Gagandeep D, Ira S. Clostridium difficile enteritis 9 years after total proctocolectomy: a rare case report. Am J Gastroenterol. 2010;105(4):962-3.
  8. Khan MS, Levy D, Mann S. Clostridium difficile infection in the absence of a colon. BMJ Case Rep. 2010 Oct 21;2010:bcr0220102728.
  9. Kim JH, Muder RR. Clostridium difficile enteritis: a review and pooled analysis of the cases. Anaerobe. 2011;17(2):52-5.
  10. Kim KA, Wry P, Hughes E, et al. Clostridium difficile small-bowel enteritis after total proctocolectomy: a rare but fatal, easily missed diagnosis. Report of a case. Dis Colon Rectum. 2007;50(6):920-3.
  11. Kurtz LE, Yang SS, Bank S. Clostridium difficile-associated small bowel enteritis after total proctocolectomy in a Crohn’s disease patient. J Clin Gastroenterol. 2010;44(1):76-7.
  12. Lundeen SJ, Otterson MF, Binion DG, et al. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg. 2007;11(2):138-42.
  13. Nasser H, Munie S, Shakaroun D, et al. Clostridium difficile Enteritis after Total Abdominal Colectomy for Ulcerative Colitis. Case Rep Crit Care. 2019;2987682.
  14. Navaneethan U, Giannella RA. Thinking beyond the colon-small bowel involvement in clostridium difficile infection. Gut Pathog. 2009;1(1):7.
  15. Peacock O, Speake W, Shaw A, et al. Clostridium difficile enteritis in a patient after total proctocolectomy. BMJ Case Rep. 2009;2009:bcr10.2008.1165.
  16. Seril DN, Shen B. Clostridium difficile infection in the postcolectomy patient. Inflamm Bowel Dis. 2014;20(12):2450-69.
  17. Tarasiuk-Rusek A, Shah KJ. Clostridium difficile ileitis in a patient, after total colectomy. BMJ Case Rep. 2016 Feb 22;2016:bcr2015214319.
  18. Vesoulis Z, Williams G, Matthews B. Pseudomembranous enteritis after proctocolectomy: report of a case. Dis Colon Rectum. 2000;43(4):551-4.
  19. Wee B, Poels JA, McCafferty IJ, et al. A description of CT features of Clostridium difficile infection of the small bowel in four patients and a review of literature. Br J Radiol. 2009;82(983):890-5.
  20. Williams RN, Hemingway D, Miller AS. Enteral Clostridium difficile, an emerging cause for high-output ileostomy. J Clin Pathol. 2009;62(10):951-3.
  21. Yafi FA, Selvasekar CR, Cima RR. Clostridium difficile enteritis following total colectomy. Tech Coloproctol. 2008;12(1):73-4.
  22. El Muhtaseb MS, Apollos JK, Dreyer JS. Clostridium difficile enteritis: a cause for high ileostomy output. ANZ J Surg. 2008 May;78(5):416.
  23. Kayal M, Tixier E, Plietz M, et al. Clostridioides Difficile Infection Is a Rare Cause of Infectious Pouchitis. Inflamm Intest Dis. 2020;5(2):59-64.
  24. Seril DN, Shen B. Clostridium difficile infection in patients with ileal pouches. Am J Gastroenterol. 2014;109(7):941-7.
  25. Li Y, Qian J, Queener E, et al. Risk factors and outcome of PCRdetected Clostridium difficile infection in ileal pouch patients. Inflamm Bowel Dis. 2013;19(2):397-403.
  26. Shen BO, Jiang ZD, Fazio VW, et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2008;6(7):782-8.
  27. Shen B, Goldblum JR, Hull TL, et al. Clostridium difficileassociated pouchitis. Dig Dis Sci. 2006;51(12):2361-4.
  28. Mann SD, Pitt J, Springall RG, et al. Clostridium difficile infection-an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum. 2003;46(2):267-70.
  29. Martinez Ugarte ML, Lightner AL, Colibaseanu D, et al. Clostridium difficile infection after restorative proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis. Colorectal Dis. 2016;18(5):O154-7.
  30. Shen B, Remzi FH, Fazio VW. Fulminant Clostridium difficileassociated pouchitis with a fatal outcome. Nat Rev Gastroenterol Hepatol. 2009;6(8):492-5.

Download Tables, Images & References

RE-INTRODUCTION: LIVER DISORDERS SERIES

Re-Introduction: Liver Disorders Series

Read Article

In 2014, Practical Gastroenterology first introduced a series of review articles with the goal of providing a detailed review of many aspects of the management of liver and biliary diseases, intended for professionals to use as reference points in their clinical practices. Today, we re-introduce a new series of liver-related articles, to continue and expand upon this purpose.

Fostering a foundation of knowledge related to liver disease management remains a highly relevant practice for all clinicians. The CDC estimates that 4.5 million adults in the United States, nearly 2% of the population, carry a diagnosis of liver disease, which is responsible for over 44,000 deaths per year.1 The economic burden of chronic liver disease to the United States remains substantial. Considering just inpatient costs, the national hospitalization costs in patients with chronic liver disease exceeds $81 billion, while, on the ambulatory side, in considering only nonalcoholic fatty liver disease, or NAFLD, which affects roughly 100 million Americans, costs accrued by the United States healthcare system in 2018 reached $32 billion annually.2,3 While liver diseases such as chronic hepatitis B and C and hemochromatosis are now relatively easy to control and prevent progression, or cure, current management options for alcohol use disorder and NAFLD remain suboptimal, despite the high prevalence of these diseases. Consequently, the prevalence of advanced liver disease and cirrhosis remains high, with over 600,000 patients estimated to have cirrhosis in the United States.4 For many patients with decompensated cirrhosis, liver transplantation remains the only option to significantly improve mortality. The total cost billed for a liver transplant from 30 days prior to transplant to 6 months after transplant was estimated to average $577,000.5

For a practicing clinician, having a solid understanding of the diagnosis and management of liver-related conditions is essential to optimizing the care and prognoses of their patients. In most cases, early diagnosis is optimal. The goal of this series is to provide timely and relevant reviews on a variety of liver diseases, highlighting the most recent advances and management strategies published in the medical literature. We aim to provide information, and will focus our selections of topics, so as to be relevant to general gastroenterologists and primary care providers, who are on the front lines of patient care. Our first review, appearing in this issue, will detail the diagnosis and management of autoimmune liver disease variants. Future articles in this series will address topics including acute liver failure, hepatic encephalopathy, drug-induced liver injury, intrahepatic cholestasis, dietary approaches to the management of NAFLD, evaluation of solid liver lesions, and a review of newer concepts in pre- and post-liver transplant care directed towards the primary care provider.

References

  1. Summary Health Statistics Tables for U.S. Adults: National Health Interview Survey, 2018, Table A-4b, A-4c.
  2. JAMA Netw Open. 2020;3(4):e201997. doi:10.100 /jamanetworkopen.2020.1997
  3. Intermountain Medical Center. “Economic burden of fatty liver disease in US is $32 billion annually, new study finds.” ScienceDaily. www.sciencedaily.com/ releases/2018/07/180703105956.htm
  4. Journal of Clinical Gastroenterology: September 2015 – Volume 49 – Issue 8 – p
    690-696
  5. Google

Download Tables, Images & References

FROM THE PEDIATRIC LITERATURE

Underreporting of Nonalcoholic Fatty Liver Disease

Read Article

Nonalcoholic fatty liver disease (NAFLD) is not uncommon in children and can be associated with hepatic fibrosis with the risk of long-term associated mortality. Thus, early detection is important in order to monitor disease activity and to provide resources to improve health outcomes. Children often undergo computed tomography (CT) of the abdomen for various reasons, and the authors of this study evaluated for incidental hepatic steatosis findings in a group of children undergoing CT for nephrolithiasis.

This retrospective, single-center study included patients younger than 18 years of age who underwent abdominal CT imaging for concern of nephrolithiasis over a 5-year period. Patients with known medical conditions that could cause steatosis such as metabolic/storage diseases, Wilson disease, autoimmune hepatitis, and viral hepatitis were excluded. Patients with asplenia also were excluded. Patient parameters including height, weight, age, and standard laboratory data were obtained from the electronic medical record. Liver and spleen parenchymal attenuation were measured with moderate-to-severe steatosis defined as a histologic fat concentration greater than 30%. This value (defined as “original criteria”) was obtained by using specific parameters of liver and spleen attenuation differences calculated as Hounsfield Units on CT. Mild steatosis was defined as histologic fat concentrations ≥ 5% and was determined using mDIXON-Quant magnetic resonance imaging to calculate Hounsfield Units (defined as “secondary criteria”). These two criteria categories were compared to patients who underwent CT for nephrolithiasis who did not have hepatic steatosis. Kappa statistics were used to determine degree of agreement of imaging findings between 2 radiologists. A total of 584 patients with appropriate inclusion criteria underwent abdominal CT for a diagnosis of nephrolithiasis during this period. Most patients were non-Hispanic females, and the median age of the patients was 14.8 years. The median body mass index (BMI) was at the 73rd percentile with 41% of patients being defined as overweight or obese. It was noted that 541 patients had no steatosis on imaging while 42 patients did have steatosis. The two CT criterium (“original” for moderate to severe; “secondary” for mild) used to determine steatosis demonstrated a prevalence rate of steatosis between 3%-35%. Kappa statistics between radiologists showed excellent correlation of findings. No significant difference in ethnicity was found between patients with or without steatosis. However, BMI percentiles and median serum alanine aminotransferase (ALT) levels were significantly higher in patients with any degree of steatosis compared to patients with no steatosis. Steatosis ranged between 6%-47% in those patients who were overweight or obese compared to 0.3%24% of patients with a normal BMI percentile. Additionally, steatosis was present in 11%-43% of patients with elevated ALT levels while steatosis was present in 0.7%-27% of patients with normal ALT levels. Finally, using a non-contrast CT liver attenuation value of less than 48 Hounsfield Units, only 12 of 42 patients (29%) had steatosis reported in the original radiology reports, and only 2 of these 12 patients had a known history of NAFLD.

This study suggests that steatosis can be found during CT imaging of the abdomen ordered for non-hepatic reasons. If steatosis is found, it is essential to have such patients be referred to pediatric gastroenterology to assist with diagnosis and treatment options to prevent the long-term complications of NAFLD.

Okura H, Yodoshi T, Thapaliya S, Trout A, Mouzaki M. Under-reporting of hepatic steatosis in children: a missed opportunity for early detection. Journal of Pediatrics 2021; 234: 92-98.

Download Tables, Images & References

FROM THE PEDIATRIC LITERATURE

Could Glucocorticoids Improve Enteral Feeding?

Read Article

Short bowel syndrome (SBS) in children is a rare disease with extremely high health care costs due to long-term parenteral nutrition (PN) requirements and the potential for frequent hospitalizations. Many patients can have PN requirements reduced or can wean from PN completely if enteral nutrition can be advanced successfully. However, risk factors such as production of inflammatory mediators and bacterial overgrowth can lead to intestinal inflammation in pediatric patients with SBS, and the authors of this study looked at the potential benefit of glucocorticoids in this specific population.

This retrospective study from a medical center with expertise in pediatric intestinal rehabilitation looked at all pediatric patients with SBS at their institution who had undergone glucocorticoid therapy for intestinal inflammation diagnosed by endoscopy with biopsy. Patients on glucocorticoids for organ transplantation or food allergy therapy were excluded. Those patients with SBS and who received glucocorticoid therapy received either prednisone or budesonide. Specifically, patients with high parenteral nutrition needs initially were placed on prednisone and then tapered to budesonide with sulfasalazine. Sulfasalazine was added if colonic inflammation was present. Patients with lower parenteral nutrition needs were initially placed on budesonide and sulfasalazine, and budesonide was eventually weaned off. All patients had linear growth monitored, and bone age and bone density were checked annually. Standard laboratory data was reviewed as well.

A total of 15 patients (9 girls) were included in this study. Gastroschisis was the leading cause of SBS occurring in 10 of the patients, and the median small bowel length for this patient group was 46 centimeters with most patients having at least half of their colon length conserved. Significant bowel inflammation with associated eosinophilia was present in the biopsies of 6 patients. The median age of starting glucocorticoid therapy and the median length of time these patients were on parenteral nutrition was 3.3 years. The median time of glucocorticoid therapy was 18 months (range 1-64 months). The ability to wean parenteral nutrition occurred in 11 patients once glucocorticoid therapy was initiated, and 7 patients were able to stop parenteral nutrition. The authors noted that linear growth was not affected, and no metabolic bone disease occurred in the study group.

Although the results are encouraging, it is still unknown if glucocorticoid therapy has the potential to reduce or remove parenteral nutrition needs in pediatric patients with SBS. The exact mechanisms for improvement in such patients are unknown (including the potential of intestinal microbiome changes), and a randomized controlled trial for this type of therapy is needed.

Wang F, Gerhardt B, Iwansky S, Hobson B, Logan S, Mercer D, Quiros-Tejeira R. Glucocorticoids improve enteral feeding tolerance in pediatric short bowel syndrome with chronic intestinal inflammation. Journal of Pediatric Gastroenterologists and Nutrition 2021; 73: 17-22.

Download Tables, Images & References

FROM THE LITERATURE

Endoscopic Sleeve Gastroplasty in Treatment of NAFLD

Read Article

A total of 118 patients with obesity and NAFLD (nonalcoholic fatty liver disease), underwent endoscopic sleeve gastroplasty (ESG) and were followed for 2 years. Weight loss was evaluated as percentage total body weight loss. Insulin resistance (IR) was evaluated using the homeostasis model assessment of insulin resistance (HOMA-IR).

Previously evaluated hepatic steatosis index and NAFLD fibrosis score were used to estimate hepatic steatosis and risk of fibrosis.

Lean body mass index was 40 kg/m². At baseline, 84% of patients completed 2 years of follow-up. At 2 years, the mean total body weight loss was 15.5%.  Patients’ HOMA-IR improved significantly from 6.7 average to 3 average after one week from ESG performance, with continued improvement up to 2 years. Patient’s hepatic steatosis index score improved significantly, decreasing by 4 points per year. Patient’s NAFLD fibrosis score improved significantly, decreasing by 0.3 per year. A total of 24 patients (20%), improved their risk of hepatic fibrosis from F3 to F4, or indeterminate to F0 to F2, whereas only 1% experienced an increase in the estimated risk of fibrosis. It was concluded there was a significant and sustained improvement in estimated hepatic steatosis and fibrosis after ESG in patients with NAFLD and it was demonstrated early and weight-independent improvement in insulin resistance, which lasted for 2 years after the procedure.

Hajifathalkian, K., Mehta, A., Ang, B., et al. “Improvement in Insulin Resistance and Estimated Hepatic Steatosis and Fibrosis After Endoscopic Sleeve Gastroplasty.”  Gastrointestinal Endoscopy 2021; Vol. 93, pp. 1110-1118.

Download Tables, Images & References

Need for Second-Look Endoscopy with an Acute Peptic Ulcer Bleed

Read Article

A meta-analysis to evaluate the usefulness of routine second-look endoscopy in patients with acute upper GI bleed because of peptic ulcer disease (PUD), with evidence of hemostasis was carried out. Several databases from inception to September 15, 2020 were evaluated to identify randomized controlled trials (RCTs) that compared routine secondlook endoscopy with no planned second-look endoscopy in patients with upper GI bleed from PUD.

The outcomes of interest included recurrent bleeding, mortality, need for surgery, and mean number of units of blood transfused. For categorical variables, pooled risk ratios were calculated (RRs), with 95% confidence intervals (CIs). For continuous variables, standardized mean difference was calculated with 95% CIs. Data was analyzed using a random effects model: the grading of recommendations, assessment, development and evaluation (GRADE) framework to ascertain the quality of the evidence. 

Nine RCTs were included, comprising 1452 patients; 726 patients underwent planned routine second-look endoscopy and 726 did not. There was no significant difference in recurrent bleeding, need for surgery, mortality or mean number of units of blood transfused.  Quality of evidence ranged from low to moderate, based on the GRADE framework.

It was concluded that single endoscopy with complete endoscopic hemostasis is not inferior to routine second-look endoscopy in reducing the risk of recurrent bleeding, mortality, or need for surgery in patients with acute upper GI bleed from PUD. 

Kamal, F., Han, N., Lee-Smith, W., et al. “Role of Routine Second-Look Endoscopy in Patients With Acute Peptic Ulcer Bleeding: Meta-Analysis of Randomized Controlled Trials.” Gastrointestinal Endoscopy 2021; Vol. 93, pp. 1228-1237.

Download Tables, Images & References

FROM THE LITERATURE

Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis

Read Article

To understand the inter-relationships between esophageal motility, lung mechanics and reflux (particularly proximal reflux – a prerequisite of aspiration), and pulmonary function in patients with IPF, 35 patients were prospectively recruited with IPF, aged 53 to 75 years and 27 of whom were men. These underwent highresolution impedance manometry and 24hour pH-impedance, together with pulmonary function assessment.

A total of 22 patients (63%), exhibited dysmotility and 16 (73%) exhibited ineffective esophageal motility (IEM); 6 (27%) exhibited esophagogastric junction outflow obstruction.

Patients with IEM have more severe pulmonary disease and more proximal reflux than patients with normal motility. In patients with IEM, intrathoracic pressure adversely correlated with the number of proximal events. Surprisingly, inspiratory lower esophageal sphincter pressure (LESP) positively correlated with the percentage of reflux events reaching the proximal esophagus, whereas in patients with normal motility, it inversely correlated with a bolus exposure time and number of proximal events.

Percentage forced vital capacity in patients with IEM inversely correlated with inspiratory LESP and positively correlated with intrathoracic pressure. 

The study demonstrated that pulmonary function is worse in patients with IEM, which is associated with more proximal reflux events, the latter correlating with lower intrathoracic pressures and higher LESPs.

Cheah, R., Chirnaksorn, S., Abdelrahim, A., et al.  “The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis.” American Journal of Gastroenterology, 2021; Vol. 116, pp. 1189-1200.

Download Tables, Images & References

Jojobet GirişmatbetcasibomcasibomcasibomGrandpashabetgrandpashabetcasibom girişCasibomcasibommavibetcasibomMeritkingGrandpashabetCasibomgrandpashabetcasibombetpasjojobet girişjojobetKickmavibetmatbetcasibominterbahisMadridbetMadridbetMadridbetJojobetgrandpashabetHoliganbet girişgrandpashabetJojobetcasibomgrandpashabetjojobetcasibomjojobetjojobetcasibomcasibom girişgrandpashabetholiganbetBetpasgrandpashabet güncel girişjojobetjojobet girişgrandpashabet